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Objective: Little is known about the temporal impact of the rapid scale-up of large
antiretroviral therapy (ART) services on programme outcomes. We describe patient
outcomes [mortality, loss-to-follow-up (LTFU) and retention] over time in a network of
South African ART cohorts.
Design: Cohort analysis utilizing routinely collected patient data.
Methods: Analysis included adults initiating ART in eight public sector programmes
across South Africa, 2002–2007. Follow-up was censored at the end of 2008. Kaplan–
Meier methods were used to estimate time to outcomes, and proportional hazards
models to examine independent predictors of outcomes.
Results: Enrolment (n¼44177, mean age 35 years; 68% women) increased 12-fold
over 5 years, with 63% of patients enrolled in the past 2 years. Twelve-month mortality
decreased from 9% to 6% over 5 years. Twelve-month LTFU increased annually from
1% (2002/2003) to 13% (2006). Cumulative LTFU increased with follow-up from 14%
at 12 months to 29% at 36 months. With each additional year on ART, failure to retain
participants was increasingly attributable to LTFU compared with recorded mortality.
At 12 and 36 months, respectively, 80 and 64% of patients were retained.
Conclusion: Numbers on ART have increased rapidly in South Africa, but the pro-
gramme has experienced deteriorating patient retention over time, particularly due to
apparent LTFU. This may represent true loss to care, but may also reﬂect administrative
error and lack of capacity to monitor movements in and out of care. New strategies are
neededforSouthAfricaandotherlow-incomeandmiddle-incomecountriestoimprove
monitoring of outcomes and maximize retention in care with increasing programme
size.  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
South Africa has the largest antiretroviral therapy (ART)
programme in the world [1]. Between 2004 (the start of
the national ART programme) and 2007, an estimated
370000 people initiated treatment in the public sector
[2]. But, despite the scope and rapid growth of this
programme there are no data on programme outcomes at
a national level. The International Epidemiologic
Databases to Evaluate AIDS collaboration of Southern
Africa (IeDEA-SA) has assembled a series of HIV
treatment cohorts from across the country that include
approximately 10% of all adults who initiated public
sector ART in South Africa by the end of 2007. The aim
of this paper is to describe trends in mortality, loss-to-
follow-up (LTFU) and programme retention of these
adult patients over the ﬁrst 5 years of the country’s
national ART programme.
Methods
Study design, population and eligibility criteria
The South African cohorts of IeDEA-SA have been
described in detail elsewhere [3]. Brieﬂy, the collabor-
ation includes eight adult cohorts providing ambulatory
ART services located in the four largest provinces in the
country (Western Cape, Free State, Gauteng and
Kwazulu-Natal). This analysis included all HIV-positive
adults ( 16 years) who initiated ART in these cohorts
between 2002 and 2007.
Variables and deﬁnitions
Baseline characteristics included demographics (age, sex),
available measures of disease severity (CD4 cell count,
WHO stage and viral load) and calendar year of ART
initiation. Outcome measures were mortality, LTFU and
programme retention. Deaths and transfers were deﬁned
by active or passive follow-up at site level. Patients were
deﬁned as LTFU if their last patient contact was more
than 6 months before the date of closure of the cohort
database and were censored at their last contact date.
Patients who were transferred out were censored at the
transfer date. For patients who started ART but had no
further contact with the clinic, 1 day of follow-up was
added to allow their inclusion in survival analyses.
Programme retention was deﬁned as those who were
enrolled and not dead or LTFU at analysis closure.
Person-time in the database included patients commen-
cing ART from January 2002 until December 2007.
Database closure was on or before 31 December 2008
(with minor variation across cohorts).
Analysis
Baseline characteristics were described with summary
statistics (medians, interquartile ranges and proportions).
Becauseofvariabilityinthecompletenessofbaselinedata,
patient numbers are reported for each analysis. Mean age,
median CD4 cell count and proportion in WHO Stage
IV were calculated by yearof enrolment. Temporal trends
were tested with the nonparametric test for trend across
continuous variables (age and CD4 cell count). Differ-
ences between proportions were tested with the chi-
square test. Time to death, LTFU and overall programme
retention were analysed using Kaplan–Meier methods
and presented by year of enrolment.
Separate proportional hazards regression models, strati-
ﬁed by cohort, were used to assess crude and adjusted
associations between patient characteristics and different
outcomes.Wemodelledtheproportionalhazardsofdeath
separately for different time periods as the risk factors for
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Table 1. Patient characteristics at ART initiation
a.
Characteristic
Adults ( 16 years)
n¼44177
Sex, n (%) 44177 (100)
Women, n (%) 29904 (67.7)
Age, n (%) 44177 (100)
Adults (years), median (IQR) 35.0 (29.9–41.6)
Age categories, n (%)
16–24 2306 (5.2)
25–34 17654 (40.0)
35–44 16177 (36.6)
45þ 8040 (18.2)
Year of initiation, n (%) 44177 (100)
2002/2003 1173 (2.7)
2004 5262 (11.9)
2005 9909 (22.4)
2006 13105 (29.7)
2007 14728 (33.3)
Absolute CD4 cell count (cell/ml), n (%) 36549 (82.7)
All adults, median (IQR) 103 (45–164)
CD4 cell count, categorical, n (%)
<50 9947 (27.2)
50–199 22703 (62.1)
 200 3899 (10.7)
HIV RNA level, log10 copies/ml, n (%) 18684 (42.3)
Median (IQR) 4.9 (4.4–5.4)
RNA level, categorical, n (%)
 5 Log 10405 (55.7)
>5 Log 8279 (44.3)
WHO stage, n (%) 11393 (25.8)
I 979 (8.6)
II 1335 (11.7)
III 5463 (48.0)
IV 3616 (31.7)
aWith number of patients with available data for each characteristic.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
deathvary,particularlyduringtheﬁrstyearonART[4,5].
The proportional hazards assumption was conﬁrmed
using Schoenfeld and scaled Schoenfeld residuals. Models
were built by adding relevant variables with progressively
less complete data, to preserve as many observations as
possible. Data on WHO staging, an important predictive
variable, were missing for 74% of patients. Consequently,
we present two ﬁnal models (including and excluding
WHO stage) for each time period. We report ﬁndings
from the models excluding WHO stage, and where
WHO staging impacted appreciably on results, we report
this.
AlthoughthenationalARTrolloutprogrammestartedon
1 April 2004, we included a small proportion of adults
who had received ART through donor-funded pro-
grammes prior to this date. There were no differences in
baseline characteristics between patients started in 2002/
2003andthosestartedin2004,and inasensitivityanalysis
(not shown) no aspect of the study ﬁndings was
substantively different when patients starting ART in
2002/2003 were excluded.
Data were analysed using STATA 11.0 (STATA
Corporation, College Station, Texas, USA). Two-sided
statistical tests were used at a¼0.05. All IeDEA-SA sites
obtained ethical approval from relevant local institutions
before contributing anonymized patient data to this
collaborative analysis.
Results
Patient characteristics
This analysis included 44177 adults who started ART
between2002 and end of 2007 (median age 35 years; 68%
women, Table 1), contributing a total of 66434 person-
years of follow-up [median 1.27 years, interquartile range
(IQR)0.64–2.20].Amongthosewith CD4 cell counts at
baseline (83%, n¼36549), median CD4 cell count was
103cells/ml (IQR 45–164), and 27% had a CD4 cell
count below 50cells/ml. The median baseline log viral
loadmeasures(availablefor18684participants, 42%),was
4.9copies/ml (IQR 4.4–5.4). A total of 11393 (26%)
patients had baseline staging, and 80% of these (n¼9079)
were classiﬁed as WHO stage III/IV.
Temporal changes in patient characteristics and
outcomes
Enrolment increased each calendar year, from 1173 in
2002/2003 to 14728 in 2007 (Table 2). The majority of
patients were enrolled in the past 2 years of the period
under analysis (63%, n¼27833). With each successive
year of the programme, patients were enrolled at older
ages and with less advanced HIV disease. Mean age
increased from 34 years in 2002/2003 to 37 years in 2007
(P<0.001). Median CD4 cell count increased from
68cells/ml in 2002/2003 to 113 in 2007 (P<0.001).
Over the same period, among patients with baseline
WHO staging, the proportion of patients with Stage IV
disease decreased from 50 to 28% (P<0.001).
Between 2002/2003 and 2006, 12-month reported
mortality declined from 9 to 6% (P<0.001) (Table 2,
Fig. 1a). Meanwhile 12-month LTFU increased with
each calendar year of enrolment, from 1% in 2002/2003
to 13% in 2006 (P<0.001), and 12-month programme
retention declined from 90 to 82% over the same period
(P<0.001) (Table 2). The crude effect of calendar year
persisted over 5 years of follow-up (Fig. 1a–c).
LTFU increased with duration on treatment (Table 3,
Fig. 1b) and made an increasing contribution to overall
patient attrition. At 6 months on ART, one-third of the
losses toprogrammeweredueto mortality: 5%ofpatients
had died while 9% were LTFU. By 36 months, mortality
accounted for one-quarter of patient losses: 10% were
dead and 30% were LTFU. Overall programme retention
dropped from 86% at 6 months to 71% at 24 months and
64% at 36 months.
Associations with baseline characteristics
In all time periods, there was a slight increase in the crude
and adjusted risk of death for older patients [adjusted
hazard ratio (HR) 1.03, 95% conﬁdence interval (CI)
1.02–1.04, Table 4, 12–36 months]. There was a strong
association between year of enrolment and the risk of
death on ART. With each successive year of enrolment
the risk of mortality decreased. The risk of death in the
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Table 2. Baseline characteristics and 12-month outcomes by calendar year of ART initiation.
Year of enrolment
2002/2003 2004 2005 2006 2007
Age, mean (95% CI) 34.3 (33.9–34.8) 35.7 (35.4–35.9) 35.7 (35.6–35.9) 36.2 (36.0–36.3) 36.9 (36.8–37.1)
CD4, median (IQR) (n¼36549) 68 (23–130) 87 (38–147) 102 (44–160) 106 (46–168) 113 (51–170)
Patients in Stage IV, n (%) (n¼11393) 434 (50.2) 708 (38.5) 998 (31.3) 998 (26.5) 478 (27.7)
12-month mortality % (95% CI) 8.9 (7.4–10.7) 7.2 (6.5–7.9) 7.4 (6.9–7.9) 6.2 (5.8–6.7) 5.6 (5.1–6.0)
12-month LTFU % (95% CI) 1.1 (0.6–1.9) 8.6 (7.9–9.4) 10.3 (9.7–10.9) 13.1 (12.5–13.7) 23.5 (22.7–24.3)
12-month retention % (95% CI) 90.1 (88.2–91.7) 84.8 (83.8–85.8) 83.1 (82.3–83.8) 81.5 (80.8–82.1) 72.3 (71.4–73.1)
CI, conﬁdence interval; IQR, interquartile range; LTFU, lost to follow-up.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ﬁrst 4 months on ARTamong those enrolled in 2007 was
31% lower than in those enrolled in 2002/2003 (adjusted
HR 0.69, 95% CI 0.52–0.91). Similar results were found
in the later durations on treatment.
CD4 cell count was strongly associated with early
mortalityon ART in both crude and adjusted analyses: in
the ﬁrst four months on ART, patients with CD4 cell
count below 50cells/ml had a six-fold higher risk of
mortality than those with CD4 cell count at least
200cells/ml (adjusted HR 5.85, 95% CI 4.47–7.65,
Table 4). With longer duration on ART, patients with
baseline CD4 cells count below 50cell/ml continued to
be at an elevated riskof death compared with those above
200cells/ml: the risk was nearly three-fold higher for
patients 4–12 months on treatment (adjusted HR 2.83,
95% CI 2.08–3.85) and two-fold higher for patients
12–36 months on ART (adjusted HR 1.84, 95% CI
1.24–2.71). The addition of WHO staging attenuated
theassociation betweenCD4 cellcountanddeathoverall
durations on ART, particularly in the group of patients
with CD4 cell count 50–199cells/ml at baseline.
In univariate and multivariate analysis, younger patients
were more likely to be LTFU than older (adjusted HR
0.99, 95% CI 0.98–0.99, Table 5). Year of enrolment
strongly predicted the risk of LTFU in the early and later
time periods on ART: the risk of LTFU increased
substantially with each successive year of enrolment and
the strength of the association persisted after controlling
for baseline age and CD4 cell count. After adjustment for
these factors, patients enrolled on ART in 2007 had a
12-fold increase in theriskof being LTFU duringthe ﬁrst
year on ART compared with those starting treatment in
2002/2003 (adjusted HR 11.89, 95% CI 6.36–22.25).
Those with a baseline CD4 cell count 50–199cells/ml
were less likely to be LTFU in the ﬁrst year on treatment
than those with a CD4 cell count  200 (adjusted HR
0.83, 95% CI 0.76–0.91). This association did not persist
when WHO staging was added to the model (adjusted
HR 1.03, 95% CI 0.77–1.38).
Discussion
This analysis demonstrates the increasing role played by
LTFU over time in the outcomes of the South African
national ART programme. The rapid pace of ART scale-
up in South Africa is evident from the 12-fold increase in
this analysis in the number of patients starting ART since
2002/2003, with 63% of all patients initiating ART
during 2006 and 2007 alone. While recorded mortality
has declined during this period, observed LTFU has
increased substantially and presents a major threat to
evaluating the effectiveness of the national programme.
Patient retention is a vital measure of the effectiveness of
ART services [6,7]. Retention in long-term care is
complex, especially in low-income and middle-income
countries [8–10], but not a new issue: primary healthcare
serviceshavelongfacedtheproblemofpatientattritionin
providing care for chronic diseases [6,11]. A systematic
review of ART programmes in sub-Saharan Africa found
large variation in patient retention across programmes,
ranging from 46 to 85% after 2 years on ART [12]. At the
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Fig. 1. Kaplan-Meier plots showing by year of ART initiation:
(a) 60-month mortality, (b) 60-month loss-to-follow-up and
(c) 60-month programme retention.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
start of the South African national programme, based on
experience with other chronic diseases, it was suggested
that the ART service might retain 60–80% of patients
annually [11]. Retention in the earlier years of the
programme exceeded this expectation: at 2 years, 71% of
all patients were still known to be in care, but the steady
increase in attrition duringthe ﬁrst 12 monthson ART in
successive years of enrolment is cause for concern.
Mortalityisonereasonfor patientattrition:inthiscohort,
observed mortality at 12 months was 6.6%, which is
comparable with results from other developing countries
[13]. With successive years of enrolment, 12-month
mortality decreased. This may be a true decline due to
improved coverage of services and patients enrolling with
less advanced HIV disease [14]. It is also plausible that as a
programme expands, its ability to accurately ascertain
patient deaths deteriorates, and high observed LTFU may
be associated with poor mortality ascertainment [15]. It is
likely that our study, based on routine surveillance,
underestimates true mortality in these cohorts. Recent
corrected mortality estimates for single South African
ART cohorts (based on linkage to the national death
register) found that at 3 years on ART, corrected
cumulative mortality was 12–15% [16,17] compared
with our uncorrected estimate of 10%. There is an urgent
need to improve ascertainment of deaths in low-income
and middle-income countries [18–20].
Yet even with such underestimation, mortality is not
the major reason for patient attrition in large ART
programmes in developing countries. The greater threat
to the success of the South African ART programme may
be the observation of high levels of LTFU, insofar as this
outcome reﬂects patients who have truly left care. The
size and pace of ART scale-up may have contributed to
observed LTFU. The programme has grown in size
dramatically, with our combined cohort increasing
enrolment 12-fold over 5 years. Such rapid increases
have placed considerable strain on health services that
were already overburdened [8,16,21] and may have
undermined the programme’s ability to monitor and
retainpatientsincare.During2007alone,33% ofpatients
in this study were enrolled onto ART: compared with the
2002/2003 cohort of patients, they had a 12-fold higher
riskof appearingLTFU.Inaddition,withlongerduration
on ART, observed LTFU accounted for an increasing
proportion of overall programme attrition: from 9% at
6 months to 29% at 36 months on ART.
If the rapid expansion of ART services does increase
observed LTFU, the situation may worsen as countries
continue to expand access to HIV treatment. Based on
2002 WHO treatment guidelines, adult ART coverage in
South Africa was an estimated 40% in 2008 [22]. In
addition, the South African government recently revised
its treatment guidelines to include all infected infants
<1 yearof age, pregnant women with CD4 cell counts of
350cells/ml or less and patients co-infected with TB [23].
South Africa and many other countries in sub-Saharan
Africa will need to continue to expand services while
retaining large numbers of patients in care. This will
require strengthening systems for chronic disease care in
these countries [6], where most health programmes are
oriented towards episodic illnesses and acute care.
Successfully re-orienting health systems towards long-
term chronic care will require a better understanding of
the phenomenon of LTFU. Often viewed as a single
construct, observed LTFU in an ART cohort more likely
represents a range of patient outcomes including patients
truly LTFU (i.e. lost to care) as well as those classiﬁed
LTFU through administrative error or inadequate patient
monitoring systems [15,24]. In a situation of rapid scale-
up of ART in resource-limited health systems, the ability
to capture and report patient data may become
increasingly inadequate [24]. Indeed, our results suggest
that larger cohorts may have become more subject to
these challenges in recent years. For example, the
apparently sharp increase in observed LTFU among
patients enrolled in 2007 is likely to reﬂect the cumulative
burden of increasing patient numbers on both ART
services and health informatics systems. This phenom-
enon may be particularly acute at larger and rapidly
expanding ART sites, some of which enrolled up to 50%
of their cumulative number of patients in 2007 alone.
Despite the scope of the problem of observed LTFU in
ART services in southern Africa, relatively little is known
aboutthisphenomenon.Thesecohorts,whicharelargely
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Table 3. Kaplan–Meier estimates of mortality, loss-to-follow-up and overall programme retention by duration of follow-up (nU44177 at
baseline).
Duration of follow-up n (%)
Mortality Loss-to-follow-up Overall retention
% (95% CI) % (95% CI) % (95% CI)
6 months 35627 (80.6) 4.8 (4.6–5.0) 9.3 (9.0–9.6) 86.4 (86.1–86.7)
12 months 26315 (59.6) 6.6 (6.3–6.8) 14.4 (14.1–14.8) 80.0 (79.6–80.3)
18 months 18788 (42.5) 7.6 (7.4–7.9) 18.8 (18.4–19.3) 75.0 (74.5–75.4)
24 months 13115 (29.7) 8.5 (8.2–8.8) 22.4 (21.9–22.9) 71.0 (70.5–71.5)
36 months 5486 (12.4) 9.7 (9.4–10.1) 28.7 (28.0–29.3) 64.4 (63.8–65.0)
48 months 803 (1.8) 10.6 (10.1–11.2) 33.3 (32.4–34.2) 59.6 (58.7–60.5)
60 months 185 (0.4) 12.9 (11.4–14.7) 35.8 (34.3–37.4) 55.9 (54.1–57.6)Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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active tracing (i.e. dedicated resources to undertake one
or more of the following: telephone call, home follow-
up, physician’s report and/or data linkage) [3]. However,
largely due to resource constraints, funding for patient
follow-up, particularly at this scale, is limited. There is a
small literature on factors associated with patient
retention highlighting the possible role of patient
preparation [25], treatment supporters [26], patient costs
[10,27], improved databases [24], community support
[28] and simpliﬁed services [6]. However, research is
needed to better understand observed LTFU and the
relative contributions of true LTFU (patients dropping
out of ART services) versus administrative LTFU
(patients who are retained in care but appear LTFU
due to problems with data capturing and reporting). In
contrast to these individuals, patients who are truly LTFU
are likely to be nonadherent to treatment and at higher
risk of death [16,29]. In addition, they face increased risk
of drug resistance to ART, undermining the long-term
effectiveness of treatment programmes [12,16].
Additional research is needed into the programme-level
determinants of LTFU, to better characterise patients
classiﬁed LTFU and provide insights into patients’
movements in and out of care.
This is the ﬁrst report on outcomes from multiple cohorts
intheworld’slargestantiretroviraltherapyprogramme,and
toourknowledge,thelargestanalysisofindividualsstarting
ART in sub-Saharan Africa. It is strengthened by up to
5 years of patient follow-up on more than 40000 patients.
The results are likely generalizable to the patient popu-
lationaccessingpublicsectorARTinmostofSouthAfrica
[3] where 80% of the population rely on the public sector
for services [30]. However, this analysis has several
important limitations. As is the case with other large-
scale ART programmes based on routine monitoring and
evaluation, it is constrained by issues of outcome
ascertainment and missing data [24]. Outcome ascertain-
mentshould improve as more cohorts in South Africalink
to the death register, presumably increasing observed
mortality and decreasing observed LTFU. Data complete-
ness is likely to present ongoing challenges, particularly as
programmes continue to expand. WHO staging were the
leastcompletedatapointinthisanalysis,yettheinclusionof
staging inmultivariateanalysisimpactedontheassociation
between baseline CD4 cell count and outcomes, high-
lighting the importance of complete baseline data. Finally,
this paper reports on averages across cohorts, which may
differ indataquality,completenessandoutcomeascertain-
ment. Despite these constraints, this analysis utilizes
routinely collected data to provide valuable insight into
the effectiveness of a huge national programme, and has
important implications for South Africa and for other
programmes in similar contexts.
In summary, this analysis demonstrates that the South
African national ART programme has undergone rapid
scale-up over 5 years. While recorded mortality has
declined, programme retention has deteriorated as
decreasing patient mortality has been greatly offset by
high and increasing levels of LTFU. This increased LTFU
may represent true loss to care, but also may be due to
increasing difﬁculty in monitoring patients enrolling into
care as well as patient movements in and out of care.
These possibilities require further investigation. Innova-
tive, effective strategies are needed to follow and retain
patientsinlargeHIVtreatmentprogrammeswhilerapidly
expanding access to ART services.
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